Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arch Biopartners Inc (ACHFF)

Arch Biopartners Inc (ACHFF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 66,290
  • Shares Outstanding, K 66,933
  • Annual Sales, $ 1,560 K
  • Annual Income, $ -2,880 K
  • EBIT $ -2 M
  • EBITDA $ -2 M
  • 60-Month Beta 1.50
  • Price/Sales -736.56
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $0.00 on 08/29/25
  • Next Earnings Date 03/02/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Drugs

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8770 +12.93%
on 12/31/25
1.0165 -2.57%
on 01/12/26
+0.0909 (+10.11%)
since 12/16/25
3-Month
0.6487 +52.67%
on 10/21/25
1.0165 -2.57%
on 01/12/26
+0.2949 (+42.40%)
since 10/16/25
52-Week
0.6487 +52.67%
on 10/21/25
1.4150 -30.01%
on 06/26/25
-0.3396 (-25.53%)
since 01/16/25

Most Recent Stories

More News
Arch Biopartners Announces Appointment of Dr. Patrick Vink as Chairman of the Board

TORONTO, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc . (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today the appointment of Dr. Patrick Vink as Chairman...

ARCH.VN : 1.380 (+0.73%)
ACHFF : 0.9904 (+0.99%)
Arch Strengthens its Position as a Leading Kidney Therapeutics Company with the Acquisition of a Breakthrough Platform to Develop New Drugs Targeting Chronic Kidney Disease (CKD)

Arch acquires a new CKD platform that has the potential to produce next-generation CKD drugs for the pharmaceutical industry Based on a novel mechanism of action involving IL-32 and directly implicated...

ARCH.VN : 1.380 (+0.73%)
ACHFF : 0.9904 (+0.99%)
Arch Biopartners Announces First Patient Successfully Dosed at Toronto General Hospital in Phase II Trial of LSALT Peptide Targeting Cardiac Surgery-Associated Acute Kidney Injury

First patient successfully completes dosing at Toronto General Hospital St. Michael’s Hospital is expected to be the next Canadian clinical site activated Arch is looking for additional clinical sites...

ARCH.VN : 1.380 (+0.73%)
ACHFF : 0.9904 (+0.99%)
Arch Biopartners Announces Start of Patient Recruitment in Phase II PONTIAK Trial Targeting Drug-Toxin-Related Acute Kidney Injury (AKI)

TORONTO, July 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the investigator-led Phase II trial titled...

ARCH.VN : 1.380 (+0.73%)
ACHFF : 0.9904 (+0.99%)
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)

ARCH.VN : 1.380 (+0.73%)
ACHFF : 0.9904 (+0.99%)
Arch Biopartners Adds Dr. David Luke as a Strategic Advisor, Clinical Trials

TORONTO, Aug. 05, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage...

ARCH.VN : 1.380 (+0.73%)
ACHFF : 0.9904 (+0.99%)
Canadian Treatments for COVID-19 (CATCO) Trial Receives Approval from Health Canada to Amend Protocol to include LSALT Peptide (Metablok)

LSALT Peptide (LSALT) is a novel drug candidate that targets acute organ inflammation in the lungs, liver and kidneys common in several indications,...

ARCH.VN : 1.380 (+0.73%)
ACHFF : 0.9904 (+0.99%)
Shares for Interest Debt Settlement

TORONTO, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) announced today that the...

ARCH.VN : 1.380 (+0.73%)
ACHFF : 0.9904 (+0.99%)

Business Summary

Arch Biopartners Inc. is a clinical stage company developing new drug candidates for treating organ damage caused by inflammation. Arch Biopartners Inc. is based in TORONTO.

See More

Key Turning Points

3rd Resistance Point 0.9904
2nd Resistance Point 0.9904
1st Resistance Point 0.9904
Last Price 0.9904
1st Support Level 0.9904
2nd Support Level 0.9904
3rd Support Level 0.9904

See More

52-Week High 1.4150
Fibonacci 61.8% 1.1223
Fibonacci 50% 1.0318
Last Price 0.9904
Fibonacci 38.2% 0.9414
52-Week Low 0.6487

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar